FrançaisJazz Pharmaceuticals (JAZZ): financial analysis & fundamentals
📈 See the interactive version (live chart) →
Valuation & profitability
| Metric | Value | What it means |
|---|---|---|
| P/E (price / earnings) | 17.2 | The higher, the more growth the market expects. |
| Forward P/E | 9.7 | On next year's expected earnings. Lower than current P/E = rising earnings. |
| PEG (P/E ÷ growth) | — | Below 1 = cheap given growth; above 2 = expensive. |
| Net margin | 20% | Share of revenue that ends up as profit. |
| Revenue growth | 16% | Pace of revenue growth. |
| Price-to-book | 3.4 | Price relative to book value. |
| Market cap | $16.3 B | Total market value of the company. |
| Dividend yield | — | No dividend currently. |
Income statement (by year)
| Year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2022 | $3.7 B | $-224 M | -6% |
| 2023 | $3.8 B | $415 M | 11% |
| 2024 | $4.1 B | $560 M | 14% |
| 2025 | $4.3 B | $-356 M | -8% |
📊 Open the interactive Jazz Pharmaceuticals page (charts, live news) →
Frequently asked questions
Is Jazz Pharmaceuticals stock expensive?
Jazz Pharmaceuticals has a P/E of 17.2 (forward P/E 9.7) and a PEG of —. A PEG below 1 is rather cheap given growth, above 2 is expensive. Verdict: valuation to review.
What is Jazz Pharmaceuticals's net margin?
Jazz Pharmaceuticals's net margin is about 20% — the share of revenue that ends up as net profit.
What is Jazz Pharmaceuticals's revenue?
Latest known revenue: $4.3 B for net income of $-356 M. The year-by-year breakdown is in the income statement above.
What is Jazz Pharmaceuticals's market cap?
Jazz Pharmaceuticals (JAZZ) has a market cap of about $16.3 B.
Does Jazz Pharmaceuticals pay a dividend?
No, Jazz Pharmaceuticals does not currently pay a dividend (it reinvests earnings).
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Data: Yahoo Finance, recomputed by JPI Invest. A stock can be « cheap » for a bad reason.